Imatinib and tyrosine kinase inhibition, in the management of BCR-ABL negative myeloproliferative disorders

Eitemau Tebyg

• Janus kinase 2 mutations in cases with BCR-ABL-negative chronic myeloproliferative disorders from Turkey
  gan: Yildiz, Ismail, et al.
  Cyhoeddwyd: (2017)
• Recent advances in the bcr-abl negative chronic myeloproliferative diseases
  gan: Bennett, Michael, et al.
  Cyhoeddwyd: (2006)
• Molecular approach to diagnose BCR/ABL negative chronic myeloproliferative neoplasms
  gan: Barcelos, Michelle Maccarini, et al.
  Cyhoeddwyd: (2011)
• Diagnostic Usefulness of the Janus Kinase 2 Mutation in non BCR/ABL Myeloproliferative Disorders
  gan: Bang, Soo-Mee, et al.
  Cyhoeddwyd: (2006)
• Clinicopathological spectrum of BCR-ABL-Negative myeloproliferative neoplasms with correlation with janus-associated kinase 2 mutation
  gan: Roopa Dixith, et al.
  Cyhoeddwyd: (2019-01-01)